XLO Xilio Therapeutics, Inc.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1840233 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY73.0%
TTM net income YoY80.4%
TTM EPS YoY103.2%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin-74.9%
Net margin-20.9%
FCF margin-104.8%
EBITDA margin-72.6%
Returns
ROE-38.2%
ROA-8.6%
ROIC (approx.)—
Asset turnover0.41x
Leverage & solvency
Liabilities / assets49.4%
Debt / equity0.00x
Current ratio4.72x
Interest coverage—
Cash quality & payout
Operating cash flow / net income4.95x
Accruals ratio33.8%
Payout ratio—
Capex / revenue1.3%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 | FY20222022-12-31 | FY20212021-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | $43.77M | $6.34M | — | — | — |
| R&D expense | $56.04M | $41.21M | $52.14M | $59.20M | $51.19M |
| SG&A expense | $29.71M | $24.78M | $27.00M | $29.95M | $23.86M |
| Operating income | -$41.98M | -$60.58M | -$79.13M | -$89.15M | -$75.04M |
| Pretax income | -$35.04M | -$58.24M | — | — | — |
| Income tax | $0 | $0 | $0 | $0 | $0 |
| Net income | -$35.04M | -$58.24M | -$76.40M | -$88.22M | -$75.80M |
| EBITDA | -$40.44M | -$58.94M | -$77.23M | -$87.30M | -$73.55M |
| EPS (basic) | -4.19 | -15.24 | -2.78 | -3.22 | -13.52 |
| EPS (diluted) | -4.19 | -15.24 | -2.78 | -3.22 | -13.52 |
| Balance sheet | |||||
| Cash & equivalents | $137.53M | $57.07M | $46.29M | $121.95M | $199.61M |
| Current assets | $145.03M | $60.23M | $48.13M | $124.50M | $202.52M |
| PP&E, net | $3.89M | $4.47M | $5.94M | $7.25M | $7.62M |
| Total assets | $154.69M | $71.08M | $60.93M | $139.16M | $218.06M |
| Current liabilities | $56.27M | $27.26M | $15.96M | $21.12M | $12.78M |
| Total liabilities | $119.41M | $53.48M | $24.10M | $33.52M | $32.63M |
| Shareholders' equity | $35.27M | $17.60M | $36.83M | $105.65M | $185.43M |
| Shares outstanding | 4.53M | 3.27M | 27.61M | 27.43M | 27.36M |
| Cash flow statement | |||||
| Operating cash flow | -$4.99M | -$18.38M | -$68.62M | -$75.72M | -$80.75M |
| Capital expenditure | $518,000 | $36,000 | $486,000 | $1.87M | $1.10M |
| Free cash flow | -$5.51M | -$18.41M | -$69.11M | -$77.59M | -$81.85M |
| Investing cash flow | -$518,000 | -$36,000 | -$486,000 | -$1.87M | -$1.10M |
| Financing cash flow | $87.78M | $29.20M | -$6.55M | -$69,000 | $260.67M |
| Depreciation & amortization | $1.54M | $1.64M | $1.90M | $1.85M | $1.50M |
| Stock-based compensation | $6.94M | $6.43M | $7.38M | $8.42M | $4.96M |
Free plan shows the latest 5 periods; Pro shows all 6 🔒
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.